NCT05606614API RE2T
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
The study evaluates the safety, dose selection, efficacy and safety of a single intrathecal dose of TSHA-102 in females with typical Rett syndrome.
Ongoing · not recruitingINTERVENTIONAL
Record summary
The study evaluates the safety, dose selection, efficacy and safety of a single intrathecal dose of TSHA-102 in females with typical Rett syndrome.
What this record cannot establish
Registry data requiring human review; it cannot determine eligibility or individual benefit.
Study level
Documented countryCA · US
Centre level9 Sites named in the sources
Original sourceClinicalTrials.gov
Human reviewHuman-reviewed
Centre level
Centre level · 9 Sites named in the sources · CA · US
City of Hope · Duarte · USSite opening to confirm
UC San Diego · La Jolla · USSite opening to confirm
UC San Francisco Benioff Children's Hospital · Oakland · USSite opening to confirm
Rush University Medical Center · Chicago · USSite opening to confirm
Kennedy Krieger Institute · Baltimore · USSite opening to confirm
Boston Children's Hospital · Boston · USSite opening to confirm
Washington University, St. Louis · St Louis · USSite opening to confirm
UT Southwestern Children's Medical Center · Dallas · USSite opening to confirm
CHU St. Justine · Montreal · CASite opening to confirm
Source and review
Résumé ou traduction assisté par IA : peut contenir des erreurs et ne remplace ni une relecture humaine ni un avis médical.
Source updated · Jul 7, 2026
Source updated · Jul 6, 2026
Synced · Sep 19, 2026
Published · Sep 19, 2026
Human review · Sep 19, 2026